Does PD-L1 Inhibition Enhance CAR T-Cell Therapy? Long-Term Insights from the ZUMA-6 Trial in Refractory DLBCL

MedXY Editorial Team•Jan 13, 2026•news

The Phase 1/2 ZUMA-6 trial evaluated the safety and efficacy of axicabtagene ciloleucel (axi-cel) in combination with the PD-L1 inhibitor atezolizumab in patients with refractory diffuse large B-cell lymphoma (DLBCL).
The combination demonstrated a manageable safety profile with no new safety signals; Grade 3 or higher cytokine release syndrome (CRS) occurred in 9% of patients, and neurologic events occurred in 32%.
Efficacy outcomes were robust, with a complete response (CR) rate of 54% and a median overall survival (OS) of 32.2 months at a median follow-up of 56.9 months.
Despite the theoretical synergy of checkpoint inhibition, the efficacy and CAR T-cell pharmacokinetics were largely consistent with historical data from axi-cel monotherapy (ZUMA-1).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

The Phase 1/2 ZUMA-6 trial evaluated the safety and efficacy of axicabtagene ciloleucel (axi-cel) in combination with the PD-L1 inhibitor atezolizumab in patients with refractory diffuse large B-cell lymphoma (DLBCL).
The combination demonstrated a manageable safety profile with no new safety signals; Grade 3 or higher cytokine release syndrome (CRS) occurred in 9% of patients, and neurologic events occurred in 32%.
Efficacy outcomes were robust, with a complete response (CR) rate of 54% and a median overall survival (OS) of 32.2 months at a median follow-up of 56.9 months.
Despite the theoretical synergy of checkpoint inhibition, the efficacy and CAR T-cell pharmacokinetics were largely consistent with historical data from axi-cel monotherapy (ZUMA-1).